



New Strategies for Acute Coronary Syndromes:

Exploring the Role of Oral
Factor Xa Inhibition

invitation

A satellite symposium held
on the occasion of the
ESC Congress 2008

September 1, 2008, 18:30-20:00
Cairo Room, Zone B1, Messe München, Munich, Germany



Bristol-Myers Squibb




Dear Colleagues

We are delighted to invite you to this Bristol-Myers Squibb and Pfizer jointly-sponsored symposium at ESC 2008 during which we will explore new strategies for the management of acute coronary syndromes (ACS) with particular focus on the emerging role of factor Xa inhibition in this setting.


ACS is responsible for the hospitalization of millions of patients every year and, as such, the burden placed on global healthcare systems by the associated morbidity and mortality is considerable. Currently available therapies recommended by published guidelines could potentially have a number of limitations. New and emerging anticoagulants that target specific steps in the coagulation cascade are being developed, in particular with the aim of improving the benefit:risk ratio.

During this symposium, Dr Harald Darius will introduce ACS and discuss current and historical anticoagulation treatment practices and their established benefits. He will also present evidence demonstrating the benefit of long-term anticoagulation plus antiplatelet therapy in managing ACS. Dr Shamir Mehta will move the discussion on to new and emerging treatments, highlighting the rationale for inhibition of factor Xa as a specific mechanism in the management of ACS. Finally, Dr Harrington will introduce the benefits of direct factor Xa inhibition and review the ongoing clinical development programs for novel, oral, direct factor Xa inhibitors in the secondary prevention of cardiovascular and cerebrovascular events in patients with recent ACS.

There will be opportunity for interactive discussion at the end of the session and we anticipate some lively debate between the panel and our colleagues. We look forward to seeing you in Munich.



Dr Robert Harrington



Dr Kurt Huber

New Strategies for Acute Coronary Syndromes: Exploring the Role of Oral Factor Xa Inhibition

September 1, 2008, 18:30-20:00

Cairo Room, Zone B1, Messe München, Munich, Germany

Co-chairs: Robert Harrington (USA) and Kurt Huber (Austria)

18:30-18:35

Welcome and introduction

Kurt Huber (Austria)

18:35-18:55

Acute coronary syndrome: Where we are, how we got here, and where we are going

Harald Darius (Germany)

18:55-19:20

Impact of factor Xa inhibitors on the treatment paradigm: Current and future perspectives for the management of arterial thrombosis

Shamir Mehta (Canada)

19:20-19:45

The advent of investigational, oral, direct factor Xa inhibition for the secondary prevention of acute coronary syndrome

Robert Harrington (USA)

19:45-20:00

Panel discussion

Kurt Huber (Austria)